Fda issues complete response letter (crl) for aflibercept 8 mg biologics license application solely due to an ongoing review of inspection findings at a third-party filler

No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the crl

REGN Ratings Summary

REGN Quant Ranking